AVTX
HEALTHCAREAvalo Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving AVTX Today?
No stock-specific AI insight has been generated for AVTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$21.81
Fundamentals
Trading
AVTX News
20 articles- This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A BreakoutYahoo Finance·May 6, 2026
- Avalo shares spike on skin drug data; BioNTech to cut staffBiopharmadive·May 6, 2026
- Avalo Therapeutics Announces Pricing of $375 Million Public OfferingGlobeNewswire Inc.·May 6, 2026
- Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·May 5, 2026
- Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis SuppurativaYahoo Finance·May 5, 2026
- Avalo Therapeutics Purchases Optional Milestone BuyoutYahoo Finance·Apr 28, 2026
- Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo TherapeuticsYahoo Finance·Apr 6, 2026
- Avalo Therapeutics (NASDAQ:AVTX) Is In A Good Position To Deliver On Growth PlansYahoo Finance·Apr 6, 2026
- Here Are Monday’s Top Wall Street Analyst Research Calls: Avis Budget, Carvana, Dow, Kratos Defense, Netflix, Northern Trust, PayPay,Twilio, Tyson Foods and More247 Wall St·Apr 6, 2026
- Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should KnowYahoo Finance·Apr 3, 2026
- 5 Small Drug Stocks to Buy as Sector Recovery Gains StrengthYahoo Finance·Apr 2, 2026
- CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian CancerYahoo Finance·Mar 26, 2026
- Avalo Therapeutics Reports 2025 Financial Results and Recent Business UpdatesYahoo Finance·Mar 23, 2026
- Avalo Therapeutics CEO Teases Q2 Top-Line Data for AVTX-009 Phase 2b HS LOTUS Trial at ConferenceMarketbeat·Mar 12, 2026
- Avalo Therapeutics Highlights AVTX-009 Plan, Near-Term Phase II HS Data at Healthcare ConferenceMarketbeat·Mar 5, 2026
- Avalo Therapeutics Highlights AVTX-009 HS Phase II Catalyst, Cash Runway at Oppenheimer ConferenceMarketbeat·Feb 26, 2026
- Avalo Therapeutics to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 24, 2026
- Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Feb 18, 2026
- Avalo Therapeutics Eyes Q2 2026 Phase IIb LOTUS Readout for AVTX-009 in Hidradenitis SuppurativaMarketbeat·Feb 11, 2026
- Leukocyte Adhesion Deficiency Market Analysis and Forecast, 2025-2035, Featuring Rocket Pharmaceuticals, Avalo Therapeutics, Orpha Labs, and AUG TherapeuticsYahoo Finance·Nov 12, 2025
All 20 articles loaded
Price Data
52-Week Range
$21.81
Fundamentals
Trading
About Avalo Therapeutics Inc
Avalo Therapeutics Inc is a prominent clinical-stage biotechnology company focused on developing innovative therapies for rare and underserved diseases, particularly those involving immunological regulation. The firm has a robust pipeline of proprietary drug candidates aimed at addressing serious conditions with significant unmet medical needs, reflecting its commitment to advancing healthcare solutions. Avalo's deep expertise in disease mechanisms and comprehensive clinical trial methodologies position it strategically within the biopharmaceutical landscape, enabling the development of transformative therapies. With a strong patient-centric approach, Avalo is poised to enhance therapeutic outcomes and drive meaningful impacts in the lives of patients.